1. Introduction {#sec1-jcm-08-00066}
===============

Acute kidney injury (AKI) is a complex clinical syndrome, characterized by an abrupt decrease in glomerular filtration, associated with various etiologies and pathophysiological pathways \[[@B1-jcm-08-00066],[@B2-jcm-08-00066],[@B3-jcm-08-00066],[@B4-jcm-08-00066],[@B5-jcm-08-00066],[@B6-jcm-08-00066]\]. Globally, AKI is a common condition, affecting 13.3 million patients a year \[[@B3-jcm-08-00066],[@B4-jcm-08-00066]\]. This complex syndrome is associated with significant morbidity, considerable mortality resulting in 1.7 million deaths a year, and increased hospital costs and subsequent burden on national health care budgets across the world \[[@B7-jcm-08-00066],[@B8-jcm-08-00066]\].

Total hip arthroplasty (THA) is one of the most consistently successful and cost-effective orthopedic procedures performed today. It is indicated in patients with severe hip pain from a variety of conditions and ultimately provides significant improved pain relief, functionality and quality of life \[[@B9-jcm-08-00066],[@B10-jcm-08-00066],[@B11-jcm-08-00066],[@B12-jcm-08-00066],[@B13-jcm-08-00066],[@B14-jcm-08-00066],[@B15-jcm-08-00066]\]. The total number of THA performed across the world is growing rapidly with close to 522,800 surgeries in the United States alone in 2014, making it the fourth most common operative procedure \[[@B16-jcm-08-00066],[@B17-jcm-08-00066]\].

Previous studies have demonstrated different incidence of AKI following total joint arthroplasties using standard AKI criteria ranging from 0.5% to 22% based on types of joint arthroplasties \[[@B5-jcm-08-00066],[@B18-jcm-08-00066],[@B19-jcm-08-00066],[@B20-jcm-08-00066],[@B21-jcm-08-00066],[@B22-jcm-08-00066],[@B23-jcm-08-00066],[@B24-jcm-08-00066],[@B25-jcm-08-00066],[@B26-jcm-08-00066],[@B27-jcm-08-00066],[@B28-jcm-08-00066],[@B29-jcm-08-00066],[@B30-jcm-08-00066],[@B31-jcm-08-00066],[@B32-jcm-08-00066],[@B33-jcm-08-00066],[@B34-jcm-08-00066],[@B35-jcm-08-00066],[@B36-jcm-08-00066],[@B37-jcm-08-00066],[@B38-jcm-08-00066],[@B39-jcm-08-00066],[@B40-jcm-08-00066]\]. The clinical and economic landscape of joint replacement surgeries including both general orthopedic and more specifically THA is rapidly changing, thus making it imperative for clinicians and administrators to understand the various risk factors and post-operative complications in order to better provide excellence in clinical and financial outcomes. However, despite progress in perioperative medicine, the incidence, incidence trend, and risk factors for AKI in patients following THA remain unclear \[[@B18-jcm-08-00066],[@B19-jcm-08-00066],[@B20-jcm-08-00066],[@B21-jcm-08-00066],[@B22-jcm-08-00066],[@B23-jcm-08-00066],[@B24-jcm-08-00066],[@B25-jcm-08-00066],[@B26-jcm-08-00066],[@B27-jcm-08-00066],[@B28-jcm-08-00066],[@B29-jcm-08-00066],[@B30-jcm-08-00066],[@B31-jcm-08-00066],[@B32-jcm-08-00066],[@B33-jcm-08-00066],[@B34-jcm-08-00066],[@B35-jcm-08-00066],[@B36-jcm-08-00066],[@B37-jcm-08-00066],[@B38-jcm-08-00066],[@B39-jcm-08-00066],[@B40-jcm-08-00066]\]. In addition, complication rates such as reoperation and readmission among patients undergoing THA remain high \[[@B18-jcm-08-00066],[@B19-jcm-08-00066],[@B20-jcm-08-00066],[@B21-jcm-08-00066],[@B22-jcm-08-00066],[@B23-jcm-08-00066],[@B24-jcm-08-00066],[@B25-jcm-08-00066],[@B26-jcm-08-00066],[@B27-jcm-08-00066],[@B28-jcm-08-00066],[@B29-jcm-08-00066],[@B30-jcm-08-00066],[@B31-jcm-08-00066],[@B32-jcm-08-00066],[@B33-jcm-08-00066]\]. Thus, we performed this systematic review to summarize the incidence and associated risk factors for AKI in patients undergoing THA.

2. Methods {#sec2-jcm-08-00066}
==========

2.1. Search Strategy and Literature Review {#sec2dot1-jcm-08-00066}
------------------------------------------

The protocol for this meta-analysis is registered with PROSPERO (International Prospective Register of Systematic Reviews; no. CRD42018101928). A systematic literature search of EMBASE (1988 to July 2018), MEDLINE (1946 to July 2018), and the Cochrane Database of Systematic Reviews (database inception to July 2018) was performed to evaluate the incidence of AKI in patients undergoing THA. The systematic literature review was undertaken independently by two investigators (C.T. and W.C) using the search strategy that combined the terms of "acute kidney injury" or "renal failure" and "hip arthroplasty" or "hip surgery" which is provided in Online [Supplementary Data 1](#app1-jcm-08-00066){ref-type="app"}. No language limitation was applied. A manual search for conceivably relevant studies using references of the included articles was also performed. This study was conducted by the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement \[[@B41-jcm-08-00066]\] and the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) \[[@B42-jcm-08-00066]\].

2.2. Selection Criteria {#sec2dot2-jcm-08-00066}
-----------------------

Eligible studies must be clinical trials or observational studies (cohort, case-control, or cross-sectional studies) that reported incidence of AKI in patients undergoing THA. Included studies must provide the data to estimate incidence of AKI with 95% confidence intervals (CI). Retrieved articles were individually reviewed for eligibility by the two investigators (C.T. and W.C.). Discrepancies were addressed and solved by mutual consensus. Inclusion was not limited by the size of the study.

2.3. Data Abstraction {#sec2dot3-jcm-08-00066}
---------------------

A structured data collecting form was used to obtain the following information from each study: title, name of the first author, year of the study, publication year, country where the study was conducted, definition of THA, AKI definition, incidence of AKI, and risk factors for AKI.

2.4. Statistical Analysis {#sec2dot4-jcm-08-00066}
-------------------------

Analyses were performed utilizing the Comprehensive Meta-Analysis 3.3 software (Biostat Inc, Englewood, NJ, USA). Adjusted point estimates from each study were consolidated by the generic inverse variance approach of DerSimonian and Laird, which designated the weight of each study based on its variance \[[@B43-jcm-08-00066]\]. Given the possibility of between-study variance, we used a random-effect model rather than a fixed-effect model. Cochran's *Q* test and *I*^2^ statistic were applied to determine the between-study heterogeneity. A value of *I*^2^ of 0% to 25% represents insignificant heterogeneity, 26% to 50% low heterogeneity, 51% to 75% moderate heterogeneity and 76%--100% high heterogeneity \[[@B44-jcm-08-00066]\]. The presence of publication bias was assessed by the Egger test \[[@B45-jcm-08-00066]\].

3. Results {#sec3-jcm-08-00066}
==========

A total of 410 potentially eligible articles were identified using our search strategy. After the exclusion of 162 articles based on title and abstract for clearly not fulfilling inclusion criteria on the basis of type of article, study design, population or outcome of interest, and 209 due to being duplicates, 39 articles were left for full-length review. 11 of them were excluded from the full-length review as they did not report the outcome of interest while 5 articles were excluded because they were not observational studies. Six studies \[[@B9-jcm-08-00066],[@B10-jcm-08-00066],[@B11-jcm-08-00066],[@B12-jcm-08-00066],[@B13-jcm-08-00066],[@B14-jcm-08-00066]\] were subsequently excluded because they did not use standard AKI definitions of Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease (RIFLE), Acute Kidney Injury Network (AKIN), and Kidney Disease: Improving Global Outcomes (KDIGO) classifications. Thus, 17 cohort studies \[[@B18-jcm-08-00066],[@B19-jcm-08-00066],[@B20-jcm-08-00066],[@B21-jcm-08-00066],[@B22-jcm-08-00066],[@B23-jcm-08-00066],[@B24-jcm-08-00066],[@B25-jcm-08-00066],[@B26-jcm-08-00066],[@B27-jcm-08-00066],[@B28-jcm-08-00066],[@B29-jcm-08-00066],[@B30-jcm-08-00066],[@B31-jcm-08-00066],[@B32-jcm-08-00066],[@B33-jcm-08-00066],[@B37-jcm-08-00066]\] comprising 24,158 patients undergoing THA were included into the meta-analysis of associated AKI incidence. The literature retrieval, review, and selection process are demonstrated in [Figure 1](#jcm-08-00066-f001){ref-type="fig"}. The characteristics of the included studies are presented in [Table 1](#jcm-08-00066-t001){ref-type="table"}.

3.1. Incidence of AKI in Patients Undergoing THA {#sec3dot1-jcm-08-00066}
------------------------------------------------

Overall, the pooled estimated incidence rates of AKI and severe AKI requiring dialysis following THA were 6.3% (95% CI: 3.8%--10.2%, *I*^2^ = 97%, [Figure 2](#jcm-08-00066-f002){ref-type="fig"}A) and 0.5% (95% CI: 0.1%--2.3%, *I*^2^ = 42%, [Figure 2](#jcm-08-00066-f002){ref-type="fig"}B), respectively. Subgroup analysis based on AKI definitions was performed and showed the pooled estimated incidence rates of AKI of 5.5% (95% CI: 1.3%--21.0%, *I*^2^ = 98%) by RIFLE criteria, 8.4% (95% CI: 5.2%--13.3%, *I*^2^ = 95%) by AKIN criteria, and 4.2% (95% CI: 1.9%--9.0%, *I*^2^ = 96%) by KDIGO criteria, respectively. We conducted a sensitivity analysis by excluding with patients undergoing THA for hip fractures. The pooled estimated incidence rates of AKI following THA for non-fracture indications was 5.6% (95% CI: 3.3%--9.3%, *I*^2^ = 97%). The pooled estimated incidence rates of AKI following THA among patients with fractures was 14.2% (95% CI: 11.8%--16.9%, *I*^2^ = 0%).

Subgroup analysis based on the countries by continent was performed and demonstrated pooled estimated incidence of AKI following THA of 9.2% (95% CI: 5.6%--14.8%) in Asia, 8.1% (95% CI: 4.9%--13.2%) in Australia, 7.4% (95% CI: 3.2%--16.3%) in Europe, and 2.8% (95% CI: 1.2%--17.0%) in North America.

Meta-regression of all included studies showed significant negative correlation between incidence of AKI following THA and the study year (slope = −0.37, *p* \<0.001), as shown in [Figure 3](#jcm-08-00066-f003){ref-type="fig"}.

3.2. Risk Factors for AKI in Patients Undergoing THA {#sec3dot2-jcm-08-00066}
----------------------------------------------------

Reported risk factors for AKI in patients undergoing THA are demonstrated in [Table 2](#jcm-08-00066-t002){ref-type="table"} \[[@B18-jcm-08-00066],[@B19-jcm-08-00066],[@B20-jcm-08-00066],[@B22-jcm-08-00066],[@B23-jcm-08-00066],[@B24-jcm-08-00066],[@B26-jcm-08-00066],[@B27-jcm-08-00066],[@B29-jcm-08-00066],[@B30-jcm-08-00066],[@B31-jcm-08-00066],[@B32-jcm-08-00066],[@B33-jcm-08-00066],[@B46-jcm-08-00066],[@B47-jcm-08-00066],[@B48-jcm-08-00066],[@B49-jcm-08-00066],[@B50-jcm-08-00066],[@B51-jcm-08-00066],[@B52-jcm-08-00066],[@B53-jcm-08-00066],[@B54-jcm-08-00066],[@B55-jcm-08-00066],[@B56-jcm-08-00066],[@B57-jcm-08-00066],[@B58-jcm-08-00066],[@B59-jcm-08-00066],[@B60-jcm-08-00066],[@B61-jcm-08-00066],[@B62-jcm-08-00066]\]. Older age \[[@B23-jcm-08-00066],[@B24-jcm-08-00066],[@B26-jcm-08-00066],[@B29-jcm-08-00066],[@B31-jcm-08-00066],[@B55-jcm-08-00066],[@B60-jcm-08-00066]\], higher body mass index (BMI) \[[@B19-jcm-08-00066],[@B22-jcm-08-00066],[@B23-jcm-08-00066],[@B24-jcm-08-00066],[@B26-jcm-08-00066],[@B30-jcm-08-00066],[@B31-jcm-08-00066],[@B46-jcm-08-00066],[@B47-jcm-08-00066],[@B48-jcm-08-00066],[@B49-jcm-08-00066],[@B56-jcm-08-00066],[@B57-jcm-08-00066],[@B59-jcm-08-00066]\], reduced baseline estimated glomerular filtration rate (eGFR)/chronic kidney disease (CKD) \[[@B31-jcm-08-00066],[@B54-jcm-08-00066],[@B55-jcm-08-00066],[@B57-jcm-08-00066],[@B60-jcm-08-00066]\], diabetes mellitus (DM) \[[@B24-jcm-08-00066],[@B26-jcm-08-00066],[@B31-jcm-08-00066],[@B34-jcm-08-00066],[@B47-jcm-08-00066],[@B55-jcm-08-00066],[@B57-jcm-08-00066]\], nonsteroidal anti-inflammatory drug (NSAID) \[[@B23-jcm-08-00066],[@B32-jcm-08-00066],[@B53-jcm-08-00066]\] use, and perioperative blood transfusion \[[@B23-jcm-08-00066],[@B47-jcm-08-00066],[@B53-jcm-08-00066],[@B55-jcm-08-00066]\] were consistently identified as important risk factors for AKI in patients undergoing THA.

3.3. Evaluation for Publication Bias {#sec3dot3-jcm-08-00066}
------------------------------------

Funnel plot ([Supplementary Figure S1](#app1-jcm-08-00066){ref-type="app"}) and Egger's regression asymmetry test were performed to evaluate for publication bias in analysis evaluating incidence of AKI in patients undergoing THA. There was no significant publication bias in meta-analysis assessing incidence of AKI in patients undergoing THA, *p* = 0.20.

4. Discussion {#sec4-jcm-08-00066}
=============

In this systematic review and meta-analysis, we found that patients who underwent THA had incidences of AKI (using a standard AKI definition) and AKI requiring dialysis of 6.3% and 0.5%, respectively. In addition, our findings showed a statistically significant negative correlation between incidence of AKI following THA and the study year, representing potential improvement in the AKI incidence for patients undergoing THA over time.

Similar to other types of perioperative AKI, the pathogenesis of THA-related AKI is multifactorial including intraoperative hypotension, perioperative anemia and blood transfusion, antibiotic-related AKI, and nephrotoxic agents such as NSAID use \[[@B18-jcm-08-00066],[@B19-jcm-08-00066],[@B20-jcm-08-00066],[@B22-jcm-08-00066],[@B23-jcm-08-00066],[@B24-jcm-08-00066],[@B26-jcm-08-00066],[@B27-jcm-08-00066],[@B29-jcm-08-00066],[@B30-jcm-08-00066],[@B31-jcm-08-00066],[@B32-jcm-08-00066],[@B33-jcm-08-00066],[@B46-jcm-08-00066],[@B47-jcm-08-00066],[@B48-jcm-08-00066],[@B49-jcm-08-00066],[@B50-jcm-08-00066],[@B51-jcm-08-00066],[@B52-jcm-08-00066],[@B53-jcm-08-00066],[@B54-jcm-08-00066],[@B55-jcm-08-00066],[@B56-jcm-08-00066],[@B57-jcm-08-00066],[@B58-jcm-08-00066],[@B59-jcm-08-00066],[@B60-jcm-08-00066],[@B61-jcm-08-00066],[@B62-jcm-08-00066]\]. Our study demonstrated an overall low incidence of AKI following THA of 6.3%, and comparatively much lower than AKI incidence following other types of major surgeries such as coronary artery bypass grafting (AKI incidence approximately 20%) \[[@B63-jcm-08-00066],[@B64-jcm-08-00066]\], vascular surgery (AKI incidence approximately 25%) \[[@B35-jcm-08-00066],[@B65-jcm-08-00066]\], or heart valve replacement surgery (AKI incidence approximately 35% to 47%) \[[@B66-jcm-08-00066]\]. In addition, the majority of AKI following THA is mild in severity \[[@B18-jcm-08-00066],[@B19-jcm-08-00066],[@B20-jcm-08-00066],[@B21-jcm-08-00066],[@B22-jcm-08-00066],[@B23-jcm-08-00066],[@B24-jcm-08-00066],[@B25-jcm-08-00066],[@B26-jcm-08-00066],[@B27-jcm-08-00066],[@B28-jcm-08-00066],[@B29-jcm-08-00066],[@B30-jcm-08-00066],[@B31-jcm-08-00066],[@B32-jcm-08-00066],[@B33-jcm-08-00066]\] and only 0.5% of patients undergoing THA developed severe AKI requiring dialysis, as demonstrated by our meta-analysis. Despite the low incidence of AKI among patients undergoing THA, those who develop AKI following THA still carry significant increased mortality and worse outcomes including prolonged hospital stay \[[@B39-jcm-08-00066],[@B46-jcm-08-00066],[@B67-jcm-08-00066],[@B68-jcm-08-00066]\] and hospital readmissions after THA \[[@B69-jcm-08-00066],[@B70-jcm-08-00066]\]. In addition, it is now evident that even mild AKI is still associated with poor long-term outcomes including development of cardiovascular diseases and CKD \[[@B71-jcm-08-00066],[@B72-jcm-08-00066]\]. Thus, perioperative medicine remains critically important in patients undergoing THA in order to prevent perioperative AKI \[[@B73-jcm-08-00066]\].

Our study also showed a potential improvement in the AKI incidence following THA over time. This is likely explained by advances in perioperative medicine care \[[@B73-jcm-08-00066]\]. As described earlier in this systematic review, the pathogenesis of AKI in patients undergoing THA is multifactorial. Risk factors for AKI following THA are summarized in [Table 2](#jcm-08-00066-t002){ref-type="table"}. Since older age, higher BMI, CKD, DM were consistently identified as important risk factors for AKI in patients undergoing THA \[[@B18-jcm-08-00066],[@B19-jcm-08-00066],[@B20-jcm-08-00066],[@B22-jcm-08-00066],[@B23-jcm-08-00066],[@B24-jcm-08-00066],[@B26-jcm-08-00066],[@B27-jcm-08-00066],[@B29-jcm-08-00066],[@B30-jcm-08-00066],[@B31-jcm-08-00066],[@B32-jcm-08-00066],[@B33-jcm-08-00066],[@B46-jcm-08-00066],[@B47-jcm-08-00066],[@B48-jcm-08-00066],[@B49-jcm-08-00066],[@B50-jcm-08-00066],[@B51-jcm-08-00066],[@B52-jcm-08-00066],[@B53-jcm-08-00066],[@B54-jcm-08-00066],[@B55-jcm-08-00066],[@B56-jcm-08-00066],[@B57-jcm-08-00066],[@B58-jcm-08-00066],[@B59-jcm-08-00066],[@B60-jcm-08-00066],[@B61-jcm-08-00066],[@B62-jcm-08-00066]\], clinicians and nephrologists should pay close attention to particular populations of patients. Limitation of nephrotoxic agents such as NSAIDs and a judicious use of perioperative blood transfusion should be considered \[[@B23-jcm-08-00066],[@B47-jcm-08-00066],[@B53-jcm-08-00066],[@B55-jcm-08-00066]\] for preventive measures to reduce AKI following THA. In patients undergoing THA, recent studies have demonstrated significant avoidance of NSAID use in those possessing higher AKI risk, such as patients with CKD and congestive heart failure (CHF) \[[@B29-jcm-08-00066],[@B31-jcm-08-00066]\]. In addition, in recent years, the use of hydroxyethyl starch (HES) solutions, unnecessary blood transfusions, chloride-rich intravenous fluids, and aminoglycosides have been discouraged \[[@B29-jcm-08-00066],[@B52-jcm-08-00066],[@B73-jcm-08-00066]\]. Furthermore, although the use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEI/ARB) and perioperative AKI risk remains controversial \[[@B2-jcm-08-00066],[@B74-jcm-08-00066],[@B75-jcm-08-00066]\], ACEIs/ARBs have been commonly discontinued before THA to prevent intraoperative hypotension \[[@B29-jcm-08-00066]\]. Future studies are required to assess if discontinuation of ACEIs/ARBs before THA may affect the incidence of THA-associated AKI, and whether it should be included in AKI preventative strategies and care optimization among patients undergoing THA \[[@B37-jcm-08-00066],[@B40-jcm-08-00066]\].

Several limitations in our meta-analysis are worth mentioning. First, there are statistical heterogeneities in our study. Possible sources for heterogeneities were the differences in patient characteristics between the individual studies. Studies involving large sample size observed lower AKI incidence compared to those with small sample size. Studies outside USA observed higher AKI incidence following THA, suggesting potential differences in operative surgery, antibiotic and blood transfusion, and perioperative care. Subgroup analysis based on the countries by continent demonstrated significantly different AKI incidences in each continent. Furthermore, the meta-regression analysis that demonstrated a significant negative correlation of post-THA AKI incidence with time adds the contribution of study year as a source of heterogeneity in our study. Second, there was limited data on the AKI incidence following THA from countries in South America and Africa. Third, there is a lack of data from the included studies on novel AKI biomarkers and AKI diagnosis based on urine output criteria. Lastly, this is a systematic review and meta-analysis of cohort studies and the data from population based studies were limited. Thus, future population based studies evaluating the incidence of AKI following THA are required.

In summary, there is an overall low incidence of AKI of 6.3% among patients undergoing THA. There has also been potential improvement in AKI incidence for patients undergoing THA over time.
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jcm-08-00066-t001_Table 1

###### 

Main characteristic of studies included in meta-analysis of AKI incidence in patients undergoing THA \[[@B18-jcm-08-00066],[@B19-jcm-08-00066],[@B20-jcm-08-00066],[@B21-jcm-08-00066],[@B22-jcm-08-00066],[@B23-jcm-08-00066],[@B24-jcm-08-00066],[@B25-jcm-08-00066],[@B26-jcm-08-00066],[@B27-jcm-08-00066],[@B28-jcm-08-00066],[@B29-jcm-08-00066],[@B30-jcm-08-00066],[@B31-jcm-08-00066],[@B32-jcm-08-00066],[@B33-jcm-08-00066]\].

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                                    Year   Country       Study Design   Procedures/Patients                                                                                       Number of Patients   AKI Definition                                Incidence
  -------------------------------------------------------- ------ ------------- -------------- --------------------------------------------------------------------------------------------------------- -------------------- --------------------------------------------- ------------------
  Ulucay et al. \[[@B18-jcm-08-00066]\]                    2012   Turkey        Cohort         Cemented bipolar hip arthroplasty for femur neck fracture; aged ≥65 years                                 163                  Acute kidney injury; AKIN criteria            25/163 (15.3%)\
                                                                                                                                                                                                                                                                            Dialysis\
                                                                                                                                                                                                                                                                            3/163 (1.8%)

  Choi et al. \[[@B1-jcm-08-00066],[@B19-jcm-08-00066]\]   2013   South Korea   Cohort         Total hip replacement for avascular necrosis                                                              489                  Acute kidney injury; AKIN criteria            47/489 (9.6%)

  Challagunda et al. \[[@B20-jcm-08-00066]\]               2013   UK            Cohort         Elective hip surgery                                                                                      112                  Acute kidney injury; RIFLE criteria           33/112 (29.5%)

  Craxford et al. \[[@B21-jcm-08-00066]\]                  2014   UK            Cohort         Total hip replacement                                                                                     200                  Acute kidney injury; RIFLE criteria           7/200 (3.5%)

  Li et al. \[[@B22-jcm-08-00066]\]                        2014   China         Cohort         Total hip replacement                                                                                     900                  Acute kidney injury; AKIN criteria            93/900 (10.3%)

  Kimmel et al. \[[@B23-jcm-08-00066]\]                    2014   Australia     Cohort         Primary elective total hip arthroplasty                                                                   173                  Acute kidney injury; RIFLE criteria           14/173 (8.1%)

  Hassan et al. \[[@B37-jcm-08-00066]\]                    2015   Denmark       Cohort         Primary hip replacement                                                                                   586                  Acute kidney injury; RIFLE criteria           81/586 (13.8%)

  Warth et al. \[[@B24-jcm-08-00066]\]                     2016   USA           Cohort         Total hip arthroplasty                                                                                    488                  Acute kidney injury; AKIN criteria            22/488 (4.5%)\
                                                                                                                                                                                                                                                                            Dialysis\
                                                                                                                                                                                                                                                                            0/488 (0%)

  Nowicka et al. \[[@B25-jcm-08-00066]\]                   2016   UK            Cohort         Elective hip arthroplasty                                                                                 156                  Acute kidney injury; AKIN criteria            11/156 (7.1%)\
                                                                                                                                                                                                                                                                            Dialysis\
                                                                                                                                                                                                                                                                            0/156 (0%)

  Choi et al. \[[@B2-jcm-08-00066],[@B26-jcm-08-00066]\]   2016   South Korea   Cohort         Total hip replacement                                                                                     2467                 Acute kidney injury; AKIN criteria            119/2467 (4.8%)

  Johansson et al. \[[@B27-jcm-08-00066]\]                 2016   Denmark       Cohort         Elective total hip replacement                                                                            136                  Acute kidney injury; KDIGO criteria           27/136 (19.9%)

  Perregaard et al. \[[@B28-jcm-08-00066]\]                2016   Denmark       Cohort         Primary elective total hip replacement                                                                    3416                 Acute kidney injury; KDIGO criteria           75/3416 (2.2%)

  Ferguson et al. \[[@B29-jcm-08-00066]\]                  2017   UK            Cohort         Primary hip arthroplasty                                                                                  187                  Acute kidney injury; KDIGO criteria           20/187 (10.7%)\
                                                                                                                                                                                                                                                                            Dialysis\
                                                                                                                                                                                                                                                                            0/187 (0%)

  Jiang et al. \[[@B30-jcm-08-00066]\]                     2017   USA           Cohort         Total hip arthroplasty                                                                                    411                  Acute kidney injury; RIFLE criteria           30/411 (7.3%)

  Gharaibeh et al. \[[@B31-jcm-08-00066]\]                 2017   USA           Cohort         Total hip arthroplasty                                                                                    10323                Acute kidney injury; KDIGO criteria           114/10323 (1.1%)

  Weinstein et al. \[[@B32-jcm-08-00066]\]                 2018   USA           Cohort         Unilateral total hip arthroplasty with intraoperative controlled hypotension under neuraxial anesthesia   2431                 Acute kidney injury; RIFLE or AKIN criteria   45/2431 (1.9%)

  Tucker et al. \[[@B33-jcm-08-00066]\]                    2018   UK            Cohort         Primary hip arthroplasty                                                                                  1420                 Acute kidney injury; AKIN criteria            19/1420 (1.3%)
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: AKI, acute kidney injury; AKIN, Acute Kidney Injury Network;KDIGO, Kidney Disease Improving Global Outcomes; RIFLE, Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease; THA, total hip arthroplasties; UK, United Kingdom; USA, United States of America.
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Reported Risk Factors for AKI in patients undergoing THA \[[@B18-jcm-08-00066],[@B19-jcm-08-00066],[@B20-jcm-08-00066],[@B22-jcm-08-00066],[@B23-jcm-08-00066],[@B24-jcm-08-00066],[@B26-jcm-08-00066],[@B27-jcm-08-00066],[@B29-jcm-08-00066],[@B30-jcm-08-00066],[@B31-jcm-08-00066],[@B32-jcm-08-00066],[@B33-jcm-08-00066],[@B46-jcm-08-00066],[@B47-jcm-08-00066],[@B48-jcm-08-00066],[@B49-jcm-08-00066],[@B50-jcm-08-00066],[@B51-jcm-08-00066],[@B52-jcm-08-00066],[@B53-jcm-08-00066],[@B54-jcm-08-00066],[@B55-jcm-08-00066],[@B56-jcm-08-00066],[@B57-jcm-08-00066],[@B58-jcm-08-00066],[@B59-jcm-08-00066],[@B60-jcm-08-00066],[@B61-jcm-08-00066],[@B62-jcm-08-00066]\].

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                                    Risk Factors for AKI
  -------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Jafari et al. \[[@B46-jcm-08-00066]\]                    Elevated BMI, elevated baseline creatinine, history of COPD, liver disease, CHF, hypertension, underlying heart disease

  Weingarten et al. \[[@B47-jcm-08-00066]\]                Elevated BMI, DM, the number of baseline antihypertensive medications, cerebral or peripheral vascular disease, the use of general anesthesia, perioperative blood transfusion

  Ulucay et al. \[[@B18-jcm-08-00066]\]                    Lower baseline eGFR

  Choi et al. \[[@B1-jcm-08-00066],[@B19-jcm-08-00066]\]   Transplantation, increased weight

  Li et al. \[[@B22-jcm-08-00066]\]                        Transplantation, increased weight

  Challagundla et al. \[[@B20-jcm-08-00066]\]              Male, ACEI/ARB

  Nielson et al. \[[@B48-jcm-08-00066]\]                   Preoperative ACEI/ARB, BMI, CAD, intra-operative hypotension

  Kimmel et al. \[[@B23-jcm-08-00066]\]                    Older age, increased BMI, lower baseline eGFR, NSAID use, ACEI/ARB use, blood transfusion

  Ward et al. \[[@B49-jcm-08-00066]\]                      Increased BMI

  Marty et al. \[[@B50-jcm-08-00066]\]                     Postoperative resistive index

  Courtney et al. \[[@B51-jcm-08-00066]\]                  Dual antibiotics prophylaxis (cefazolin + vancomycin vs. cefazolin), ASA classification, preoperative kidney disease

  Opperer et al. \[[@B52-jcm-08-00066]\]                   Perioperative fluid resuscitation with 6% HES or 5% albumin

  Aeng et al. \[[@B53-jcm-08-00066]\]                      Gentamicin in premanufactured bone cement, intraoperative blood transfusion, postoperative NSAID use

  Warth et al. \[[@B24-jcm-08-00066]\]                     Older age, elevated BMI, DM, smoking

  Tan et al. \[[@B54-jcm-08-00066]\]                       CKD

  Nadkarni et al. \[[@B55-jcm-08-00066]\]                  Older age, male sex, black race, CKD, CHF, chronic liver disease, hypertension, DM, atrial fibrillation, HCV infection, postoperative sepsis, acute MI, blood transfusion, urban hospital, small hospital size

  Meller et al. \[[@B56-jcm-08-00066]\]                    Morbid obesity

  Choi et al. \[[@B2-jcm-08-00066],[@B26-jcm-08-00066]\]   Postoperative anemia, older age, male sex, BMI \<22 or ≥25, DM, beta-blocker, ARB use

  Ferguson et al. \[[@B29-jcm-08-00066]\]                  Older age, the use of ≥1 L of postoperative fluid

  Johansson et al. \[[@B27-jcm-08-00066]\]                 Gentamicin, female sex

  Geller et al. \[[@B57-jcm-08-00066]\]                    Higher BMI, lower baseline hemoglobin, history of comorbid condition (DM, CKD, CVD, hypertension)

  Jiang et al. \[[@B30-jcm-08-00066]\]                     Perioperative ACEI/ARB use, vancomycin use, increased BMI

  Zainudheen et al. \[[@B58-jcm-08-00066]\]                Use of renin-angiotensin antagonists

  Jamsa et al. \[[@B59-jcm-08-00066]\]                     Lower preoperative eGFR, ASA classification, BMI, duration of operation

  Ghareibeh et al. \[[@B31-jcm-08-00066]\]                 Entire cohort: older age, male, CKD, heart failure, diabetes, hypertension\
                                                           Nested case control: elevated BMI, heart failure, DM, hypertension, lower GFR, transfusion

  Yadav et al. \[[@B60-jcm-08-00066]\]                     Older age, surgery for periprosthetic joint infection, CKD, total number of surgeries

  Weinstein et al. \[[@B32-jcm-08-00066]\]                 Lower baseline GFR, lower baseline hemoglobin, previous NSAID use

  Tucker et al. \[[@B33-jcm-08-00066]\]                    Gentamicin use

  Klement et al. \[[@B61-jcm-08-00066]\]                   Co-occurrence of a mental illness and a substance abuse disorder

  Abar et al. \[[@B62-jcm-08-00066]\]                      Elevated preoperative creatinine, larger postoperative drop in hemoglobin, and higher ASA classification

  Hassan et al. \[[@B37-jcm-08-00066]\]                    Older age, hypertension, general anesthesia, high ASA score, low baseline systolic and diastolic blood pressure, hip fracture

  Dubrovskaya et al. \[[@B34-jcm-08-00066]\]               Hospital stay \>1 day prior to surgery, knee or hip surgery, DM

  Bailey et al. \[[@B38-jcm-08-00066]\]                    Prophylactic use of flucloxacillin and gentamicin versus cefuroxime alone
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: ACEI/ARB, angiotensin-converting enzyme inhibitor/angiotensin II receptor blockers; AKI, acute kidney injury; ASA, American Society of Anesthesiologists; BMI, body mass index; CAD, coronary artery disease; CHF, congestive heart failure; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; HCV, hepatitis C virus; NSAID, nonsteroidal anti-inflammatory drug; THA, total hip arthroplasties.
